OA04-06 LB. Post-infection cellular immune responses in recipients following ALVAC-HIV® + AIDSVAX® B/E prime-boost vaccination in the Thai Phase III Trial

Ítems similars

• OA07-04 LB. Immunogenicity of ALVAC-HIV® (vCP1521) and AIDSVAX® B/E prime boose vaccination in RV144, the Thai Phase III HIV vaccine trial
  per: de Souza, MS, et al.
  Publicat: (2009)
• Identification of Immunodominant CD4-Restricted Epitopes Co-Located with Antibody Binding Sites in Individuals Vaccinated with ALVAC-HIV and AIDSVAX B/E
  per: Ratto-Kim, Silvia, et al.
  Publicat: (2015)
• Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy Trial
  per: Zolla-Pazner, Susan, et al.
  Publicat: (2013)
• OA06-06 LB. Evidence of vaccine-induced changes in breakthrough HIV-1 strains from the Step trial
  per: Rolland, M, et al.
  Publicat: (2009)
• Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand.
  per: Punnee Pitisuttithum, et al.
  Publicat: (2011-01-01)